Search results
Showing 1111 to 1125 of 2008 results for nice guidelines
Discontinued Reference number: GID-NG10375
NICE has developed a medtech innovation briefing (MIB) on Accuro for guiding epidural or spinal anaesthesia .
Discontinued Reference number: GID-NG10374
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Violence and aggression: short-term management in mental health, health and community settings
Discontinued Reference number: GID-NG10397
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
This process and methods guide has been developed to help guidance‑producing centres make research recommendations. It describes a step-by-step approach to identifying uncertainties, formulating research recommendations and research questions, prioritising them and communicating them to the NICE Science Policy and Research (SP&R) team, researchers, and funders
Evidence-based recommendations on venoarterial extracorporeal membrane oxygenation (VA ECMO) for severe acute heart failure in adults. This involves using an artificial lung to oxygenate the blood outside the body.
Discontinued Reference number: GID-NG10384
Discontinued Reference number: GID-NG10396
Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)
NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .
Intrapartum care for healthy women and babies - angle of episiotomy
Discontinued Reference number: GID-NG10394
Intrapartum care for healthy women and babies - rectal examination after delivery
Discontinued Reference number: GID-NG10395
Endometriosis: diagnosis and management - surgical management - pain management post-surgery
Discontinued Reference number: GID-NG10385
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.